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Ovarian cancer patients may experience psychological disorders due to the aggressive nature of the illness and treatment. We
investigated the presence of psychological disorders longitudinally in women with a new diagnosis of ovarian cancer and the factors
that predicted development and maintenance of these disorders. Patients were assessed in a prospective longitudinal study at the
beginning of chemotherapy treatment, mid-treatment, end of treatment and 3 months follow-up for depression, anxiety, perceived
social support, neuroticism and cognitive strategies to control unwanted thoughts. A total of 121 patients were recruited and 85
patients were assessed at all four time points. Three different longitudinal profiles of anxiety and depression caseness were found:
non-cases (never cases), occasional cases (cases on at least one but not all four occasions) and stable cases (cases on all four
occasions). Most of the women were occasional cases of anxiety (52%, 44), whereas for depression, the majority of women were
non-cases (55%, 47). A subset of patients were stable cases of anxiety (22%, 19). Neuroticism and marital status were significant
independent predictors of anxiety caseness profile. Neuroticism and use of anti-depressants were independent predictors of
depression caseness profile. Social support was not related to psychological morbidity.
British Journal of Cancer (2008) 99, 1794–1801. doi:10.1038/sj.bjc.6604770 www.bjcancer.com
Published online 11 November 2008
& 2008 Cancer Research UK
Keywords: ovarian cancer; anxiety; depression; longitudinal study
                                               
Ovarian cancer is the fourth highest cause of mortality in female
cancer patients and the most fatal malignancy of the female genital
tract. It has a lifetime risk of approximately 2%. It is uncommon
before the age of 40, but the incidence increases with age, reaching
a peak in the late 70s. The disease presents, predominantly, at an
advanced stage, with a 5-year survival rate of 45%. Less than 20%
of tumours are localised at the time of diagnosis (American Cancer
Society, 2007).
Ovarian cancer patients may be at high risk of developing
psychological morbidity (Hipkins et al, 2004); however, the
evaluation of psychological morbidity, such as anxiety and
depression, has received relatively little attention. Some studies
have assessed ovarian cancer patients in samples of all women
diagnosed with gynaecological cancer (Cain et al, 1983; Andersen
et al, 1989; Petersen et al, 2005). However, as gynaecological
cancers have different profiles, the psychological challenges
associated with these various malignancies may differ (Rieger,
Touyz and Wain, 1998). Published research evaluating ovarian
cancer include mostly qualitative studies (Ferrell et al, 2002,
2003a,b,c; Howell et al, 2003) and quality-of-life studies (Guidozzi,
1993; Anderson, 1994; Kornblith et al, 1995; Ersek et al, 1997;
Borduka-Bevers et al, 2000; Lakusta et al, 2001). These studies
indicate that disruptions to quality of life may occur, which
includes significant distress, impairment in physical, vocational,
social, familial and sexual functioning. A deterioration in quality of
life was evident 2 years after the commencement of treatment
(Guidozzi, 1993). Studies assessing the prevalence of psychological
distress report rates of 22–47% for anxiety (Kornblith et al, 1995;
Borduka-Bevers et al, 2000; Hipkins et al, 2004) and 6–35% for
depression (Kornblith et al, 1995; Borduka-Bevers et al, 2000;
Wenzel et al, 2002; Hipkins et al, 2004; Norton et al, 2004).
Longitudinal studies addressing the prevalence of psychological
distress from diagnosis to follow-up are lacking. Despite some
inconsistent findings, demographic factors and medical factors
have been associated with the development of psychological
distress (Kornblith et al, 1995; Borduka-Bevers et al, 2000; Hipkins
et al, 2004; Norton et al, 2004). Poor social support has also been
associated with the presence of psychological disorders in ovarian
cancer patients (Hipkins et al, 2004). Little is known regarding
personality factors and coping strategies as risk factors of
psychological morbidity in ovarian cancer patients.
This study was designed to investigate the presence of
psychological disorders in ovarian cancer patients from immedi-
ately after diagnosis and referral to a specialist treatment centre
and over the period of their treatment and follow-up. We were
interested in identifying caseness for psychological disorders and
not just symptoms or distress, as this was considered a more
important clinical outcome and accurate assessment of significant
psychological morbidity. We used a prospective longitudinal
design, in which patients were assessed at similar time points
during their illness course and treatment. This allowed us to
investigate the course of psychological disorders over time and
identify those patients in which psychological morbidity was
persistent. We hypothesised that (i) three different psychological
morbidity profiles would appear across time, which were stable
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scases (patients who were always caseness for anxiety or depres-
sion), occasional cases (cases on some occasions of assessment but
not all) and non-cases of anxiety and depression (patients who
were never classified as cases); (ii) poor social support, high
neuroticism and use of worry as a coping strategy to control
unwanted thoughts would be associated with the development and
persistence of psychological morbidity.
MATERIALS AND METHODS
Participants
Participants were recruited from consecutive new referrals
attending the ovarian cancer outpatient clinic of Christie Hospital,
Manchester, UK, a specialist cancer centre, subsequent to their
diagnosis but before the start of their treatment. Eligible
participants were patients with a new diagnosis of ovarian,
peritoneal or fallopian tube carcinoma, who provided informed
consent, who did not have a pre-existing organic brain disorder or
severe mental illness and were able to understand English
language. Written consent was obtained from all patients.
Patients with a diagnosis of peritoneal or fallopian tube carcinoma
were recruited because they are remarkably similar in their
morphology, clinical behaviour and treatment to ovarian cancer
(Kosary and Trimble, 2002; Piek et al,2 0 0 4 ) .P a r t i c i p a n t sw e r e
recruited into the study before commencing a first-line platinum-based
chemotherapy regimen, conventionally administered every 3 weeks for
six cycles (Adams et al, 1998). Routine computed tomography scans
were performed at the start and at the end of treatment.
Procedure
New referrals to the ovarian cancer treatment centre were
approached to participate in the study at their first appointment
at the clinic. Participants who consented to take part in the study
completed the assessment measures at four time points: time 1 (T1,
first cycle of chemotherapy; beginning of treatment), time 2 (T2,
third cycle of chemotherapy; half-way treatment, approximately
6–8 weeks after T1), time 3 (T3, sixth cycle; end of chemotherapy,
approximately 15 weeks after T1), and time 4 (T4, 3 months follow-
up after cessation of treatment, approximately 27 weeks after T1).
Ethical Committee approval was obtained from the Local
Research Ethics Committee before commencement of the study.
Measures
Demographic and clinical information A structured interview
schedule was used to record general demographic and clinical
information including age, marital status, employment status and
education. Coexisting physical health problems, current mental
health problems, current psychological treatment, past mental
health problems, past psychological treatment (mental health
problems and psychological treatment were assessed as just
present or absent), current anti-depressant medication, time since
cancer diagnosis and family history of cancer were also assessed.
A subjective rating of current subjective physical health was obtained
by asking patients to rate their physical health on a 7-point scale
(0¼extremely ill to 6¼well, healthy) (Matthews et al, 1999).
Medical information Histological diagnosis, stage of disease
according to FIGO (International Federation of Gynecology and
Obstetrics), Karnofsky Performance status (KP; Karnofsky and
Buchernal, 1949), chemotherapy regimen received and response to
chemotherapy treatment (WHO, 1979) were recorded from the
clinical notes and from the medical database.
Psychological measures The following standardized psychological
measures were used; all have acceptable psychometric properties.
Anxiety and depression The Hospital Anxiety and Depression
Scale (HADS; Zigmond and Snaith, 1983) was the primary outcome
measure of psychological morbidity, anxiety and depression,
assessed at different time periods. It was administered at all time
points. The HADS is a 14-item scale that measures anxiety (seven
items) and depressive symptoms (seven items). For the identifica-
tion of clinical cases, the cutoff scores recommended for both
subscales are a score of 8 or above indicating a possible case and a
score of 11 or above indicating a probable case of anxiety or
depression. A score of 0–7 for either subscale is considered within
the normal range. In this study, scores of 8 or above were
considered as cases of anxiety and depression at that assessment
point.
Perceived social support The Social Support Inventory (SSI;
Holeva, 1998) assessed the effect of perceived criticism and
perceived social support on the development and maintenance of
psychological disorders. It was completed at time 1. It includes five
items. Two items refer to perceived criticism of, and from,
significant others and three items refer to social support. The items
are reverse-scored, so high scores indicate an absence of criticism
but poor social support. The SSI has previously been used with
ovarian cancer patients and found to predict psychological
morbidity (Hipkins et al, 2004). The SSI has good psychometric
properties: internal consistency (Cronbach alpha: social support
0.83; perceived criticism 0.67) and 4-week test–retest reliability
(social support r¼0.55; perceived criticism r¼0.79).
Coping strategies to control unwanted thoughts The Thought
Control Questionnaire (TCQ; Wells and Davies, 1994) assessed the
use of worry and other coping strategies to control unwanted
thoughts on the development and maintenance of psychological
morbidity. It was completed at time 1. It comprises 30 items, which
include five subscales that assess five strategies to control intrusive
thoughts: distraction, punishment, reappraisal, social control and
worry. It has previously been demonstrated to be predictive of the
development of psychological disorders in trauma patients (Holeva
et al, 2001). The TCQ has good psychometric properties with a
Cronbach alpha of between 0.64 and 0.79 for the five scales and a
test–retest reliability of between r¼0.68 and r¼0.83).
Neuroticism The Revised Eysenck Personality Questionnaire
(EPQ-R; Eysenck and Eysenck, 1991) evaluated the effect of
neuroticism on the development and maintenance of psychological
morbidity. It was completed at time 1. In this study, only the
Neuroticism subscale was employed. Persons scoring high in
neuroticism are described as anxious, worrying, moody and
depressed. Neuroticism is significantly associated with the
development of psychological disorders after trauma (Holeva
and Tarrier, 2001).
Statistical analysis
Data were analysed using the SPSS Version 13.0. Descriptive
statistics were used to analyse the sample characteristics and
psychological measures.
Patients were divided into three groups according to their
profile of the occurrence and persistence of anxiety and depressive
disorders across time. For both anxiety and depression separately,
the following classifications were made: (1) patients who were
never cases on any of the four assessment time points – ‘stable
non-cases’; (2) patients who were cases on at least one assessment
but not all four assessments – ‘occasional cases’; (3) patients who
were cases on all four assessments – ‘stable cases’. Cases comprised
of scoring 8 or above in the HADS anxiety or depression scale at
that assessment time point.
Non-parametric statistical tests were used to compare measures
that were categorical and where measures significantly departed
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comparisons. Tukey’s honestly significant differences (HSD) test was
used for all post hoc analyses. Multinomial Logistic Regression
analysis was performed to estimate adjusted odds ratios (ORs) and
95% confidence intervals (CIs) for confounding variables. This
method calculates ORs for a dependent variable with more than two
categories, evaluating the effect of each explanatory variable. This
analysis was performed to predict the three-category-dependent
variable: ‘stable non-cases’, ‘occasional cases’ and ‘stable cases’ of
anxiety. Binary Logistic Regression was used to predict the two-
category-dependent variable: ‘stable non-cases’ and ‘cases’ of
depression (combining occasional and stable cases). This was carried
out using Stepwise Forward (Wald) model. Patient characteristics,
medical and psychological variables identified in the univariate
analysis with a P¼0.1 (significance at a 10% level) entered the first
model of the Multinomial Logistic Regression and the Binary
Logistic Regression model. Statistical significance was set at Pp0.05.
RESULTS
Participants
From 148 patients who met the inclusion criteria, 25 refused
participation and 2 provided informed consent but failed to return
the questionnaires. The most common reasons for refusing to
participate in the study were that the patient was not interested in
the study or did not want to be reminded about their cancer. A
total of 121 patients participated in the study and completed the
measures for at least one time point, with 118 completing
assessments at T1, 106 at T2, 100 at T3 and 95 at T4. Eighty-five
patients completed all four assessment points. Eleven patients were
assessed only once, 7 only on two occasions, 17 on three occasions
and 86 on all four occasions. Eleven patients died during the
duration of the study. Table 1 shows the percentages of non-cases
and cases of anxiety and depression at each assessment point
measured by the HADS. The majority of the sample scored in the
clinical range of anxiety. The highest percentage of probable cases
of anxiety (scores 411) occurred at time 1. Most of the patients
were not cases of depression. The highest percentage of patients
scoring in the clinical range of depression occurred at time 1.
Tables 3 and 4 present the patients’ characteristics and results of
the psychological measures for the complete data set (n¼121).
Of the 121 patients, 36 were excluded from the present
longitudinal analysis due to incomplete data. Comparisons were
made, on all variables, between the 85 patients with a complete
data set and the 36 with incomplete data. Owing to the large
number of comparisons, significance was set at 1%. There were no
differences on demographic characteristics, psychological vari-
ables, time since cancer diagnosis, treatment type, stage of disease
and type of diagnosis. Those with complete data had significantly
higher KP scores (U¼1012.000, P¼0.008; medians  80 and 70,
respectively) and a better response to treatment (w
2 (2)¼9.25,
P¼0.01). It is possible that those who did not complete
assessments did so due to the severity of their illness.
The longitudinal pattern of anxiety and depression was
examined for 85 patients who completed the measures at all the
four assessment points. Patients were allocated to profile groups
depending on the occurrence and persistence of anxiety and
depression: (1) ‘stable non-cases’, (2) ‘occasional cases’, and (3)
‘stable cases’. Table 2 shows the number of patients in each profile
group according to their anxiety and depression profiles. The most
prevalent profile of anxiety was ‘occasional cases’ (52%, 44),
indicating that clinical anxiety was frequently intermittent,
whereas ‘stable non-cases’ was the most common profile of
depression (55%, 47), indicating that clinical depression was not
prevalent. The distribution of patients’ characteristics and medical
data according to the profile groups is presented in Table 3 and
psychological variables are presented in Table 4.
Anxiety
Comparisons of three anxiety profile groups were made on all
characteristic and medical data. There were statistically significant
differences among the groups with respect to age (F(2, 82)¼3.03;
Table 1 The percentages of patients who scored as a non-case (o7), as a possible case (8–10), and as a probable case (411) of anxiety and depression
at different time points for the all samples (ie, all patients assessed at that time point) and for the patients with complete data set (N¼85)
Time 1 Time 2 Time 3 Time 4
All sample
Complete
data set All sample
Complete
data set All sample
Complete
data set All sample
Complete
data set
HADS
n (%)
(N¼118)
n (%)
(N¼85)
n (%)
(N¼106)
n (%)
(N¼85)
n (%)
(N¼100)
n (%)
(N¼85)
n (%)
(N¼95)
n (%)
(N¼85)
Anxiety
Non-case (cutoff p7) 53 (45) 42 (49) 56 (53) 46 (54) 49 (49) 43 (51) 44 (46) 41 (48)
Possible case (cutoff X8t op10) 27 (22) 18 (21) 26 (25) 21 (25) 27 (27) 22 (26) 28 (30) 25 (29)
Probable case (cutoff X11) 38 (31) 25 (29) 24 (23) 18 (21) 24 (24) 20 (24) 23 (24) 19 (22)
Depression
Non-case (cutoff p7) 82 (70) 60 (71) 79 (75) 65 (77) 77 (77) 65 (77) 71 (75) 65 (77)
Possible case (cutoff X8t op10) 23 (20) 16 (19) 15 (14) 8 (9) 12 (12) 10 (12) 12 (13) 11 (13)
Probable case (cutoff X11) 13 (11) 9 (11) 12 (11) 12 (14) 11 (11) 10 (12) 12 (13) 9 (11)
HADS¼Hospital Anxiety and Depression Scale, n¼number of patients who were cases or not. Time 1¼beginning of treatment; time 2¼half-way treatment; time 3¼end of
treatment; time 4: 3-month follow-up.
Table 2 Number of patients in each group according to their profile of
anxiety and depression across time (N¼85)
HADS n %
Anxiety
Group 1 (stable non-cases) 22 26
Group 2 (occasional cases) 44 52
Group 3 (stable cases) 19 22
Depression
Group 1 (stable non-cases) 47 55
Group 2
a (occasional cases) 33 38
Group 3
a (stable cases) 5 6
HADS¼Hospital Anxiety and Depression Scale. n¼number of patients.
aGroups 2
and 3 were combined for further analysis due to the low number of patients in
group 3.
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were younger than those in stable non-cases. Groups also differed
regarding marital status (w
2 (2)¼6.11; P¼0.047) and length of
time since cancer diagnosis (F(2, 82)¼5.43; P¼0.006). The
proportion of married women was greater in stable cases.
Compared with the other two groups, patients in stable non-cases
had a longer length of time since cancer diagnosis when compared
to those in other groups.
The three groups differed significantly regarding neuroticism
(F(2, 79)¼19.04; Po0.001). Non-cases had the lowest scores of
Table 3 Distribution of patients’ characteristics for the total sample (n¼121), for the anxiety profile groups (n¼85), and for the depression profile
groups (n¼85)
Anxiety profile groups Depression profile groups
Patients’ characteristics
Total
sample,
n¼121
Group 1 (stable
non-cases),
n¼22
Group 2
(occasional cases),
n¼44
Group 3
(stable cases),
n¼19
Group 1 (occasional
non-cases),
n¼47
Group 2
(cases),
n¼38
Mean age in years (s.d.)
a 61 (12) 64 (9) 60 (12) 56 (8) 61 (10) 59 (12)
Marital status: n (%)
a,b
Married 77 (64) 12 (54.5) 28 (63.6) 17 (89.5) 31 (66.0) 26 (68.4)
Not married 44 (37) 10 (45.5) 16 (36.4) 2 (10.5) 16 (34.0) 12 (31.6)
Education: n (%)
No exams taken 56 (46) 6 (27.3) 26 (59.1) 8 (42.1) 22 (46.8) 18 (47.4)
O-levels 30 (25) 6 (27.3) 8 (18.1) 4 (21.1) 9 (19.2) 9 (23.7)
A-levels 12 (10) 4 (18.1) 1 (2.3) 3 (15.7) 4 (8.5) 4 (10.5)
Higher education 23 (19) 6 (27.3) 9 (20.5) 4 (21.1) 12 (25.5) 7 (18.4)
Employment status: n (%)
Not working 87 (72) 16 (72.7) 28 (63.6) 14 (73.7) 16 (34.0) 11 (28.9)
Working 34 (28) 6 (27.3) 16 (36.4) 5 (26.3) 31 (66.0) 27 (71.1)
Median subjective physical health rating (range)
c 4 (0–6) 4 (3–6) 4 (2–6) 5 (3–6) 5 (3–6) 4 (2–6)
Other physical health problems: n (%) 57 (47) 9 (40.9) 20 (45.4) 8 (42.1) 18 (38.3) 18 (47.4)
Current mental health problems: n (%) 17 (14) 2 (9.1) 5 (11.3) 3 (15.7) 3 (6.4) 7 (18.4)
History of mental health problems: n (%) 28 (23) 6 (27.3) 11 (25.0) 7 (36.8) 13 (27.7) 11 (28.9)
Current psychological help: n (%) 2 (2) 1 (4.5) 0 1 (5.3) 1 (2.1) 1 (2.7)
History of past psychological help: n (%) 14 (12) 3 (13.6) 4 (9.1) 4 (21.1) 7 (14.9) 4 (10.5)
Use of anti-depressants: n (%)
c 19 (16) 2 (9.1) 8 (18.1) 6 (31.6) 3 (6.4) 13 (34.2)
Family history of cancer: n (%) 75 (62) 15 (68.2) 27 (61.4) 14 (73.7) 31 (66.0) 25 (65.8)
Mean time since cancer diagnosis in days (s.d.)
a,c 53 (25) 69 (37) 48 (22) 49 (14) 61 (31) 45 (18)
Diagnosis: n (%)
d
Ovarian cancer 106 (88) 22 (100) 39 (88.6) 16 (84.3) 44 (93.6) 33 (86.8)
Primary peritoneal cancer 11 (9) 0 3 (6.8) 3 (15.7) 2 (4.3) 4 (10.5)
Fallopian tube carcinoma 4 (3) 0 2 (4.6) 0 1 (2.1) 1 (2.7)
Stage of disease: n (%)
c
Stage I 29 (24) 7 (31.9) 10 (22.7) 6 (31.6) 16 (34.0) 7 (18.4)
Stage II 4 (3) 3 (13.6) 0 1 (5.3) 3 (6.4) 1 (2.7)
Stage III 67 (55) 9 (40.9) 30 (68.2) 9 (47.4) 25 (53.2) 23 (60.5)
Stage IV 21 (17) 3 (13.6) 4 (9.1) 3 (15.7) 3 (6.4) 7 (18.4)
Median Karnofsky performance status scale value
(range)
c,e–g
80 (40–100) 80 (40–100) 80 (40–100) 80 (50–90) 80 (50–100) 80 (40–90)
Chemotherapy regimen: n (%)
Carboplatin-based 70 (58) 12 (54.5) 21 (47.7) 11 (57.9) 23 (48.9) 21 (55.3)
Other regimens 51 (42) 10 (45.5) 23 (52.3) 8 (42.1) 24 (51.1) 17 (44.7)
Response to treatment: n (%)
h–j
No measurable disease 28 (25) 8 (40.0) 8 (18.6) 7 (38.8) 16(37.2) 7 (18.4)
Complete response 24 (22) 5 (25.0) 10 (23.2) 5 (27.8) 11 (25.6) 9 (23.7)
Partial response 24 (22) 4 (20.0) 13 (30.2) 2 (11.1) 9 (20.9) 10 (26.3)
Stable disease 17 (15) 2 (10.0) 6 (14.0) 3 (16.7) 4 (9.3) 7 (18.4)
Progressive disease 18 (16) 1 (5.0) 6 (14.0) 1 (5.6) 3 (7.0) 5 (13.2)
n¼number of patients; s.d.¼standard deviation.
aIndicates statistically significant differences in the anxiety profile groups.
bGrouping of categories was employed because
frequencies were less than 5.
cIndicates statistically significant differences in the depression profile groups.
dGrouping of categories was used because frequencies were less than 5.
eThere were no available data for three patients in the total sample.
fThere were no available data for two patients, one from group 1 and one from group 2 in the anxiety profile
groups.
gThere were no available data for two patients, one from group 1 and one from group 2 in the depression profile groups.
hThere were no available data for 10 patients in
the total sample.
iGrouping of categories were used because frequencies were less than 5. There were no available data for two patients from group 1, one patient from group2
and one patient from group 3 in the anxiety profile groups.
jGrouping of categories were used because frequencies were less than 5. There was no available data for four patients
from group 1 in the depression profile groups.
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neuroticism. Higher levels of neuroticism were associated with
higher rates of anxiety, which tended to be persistent (stable
cases). The three groups also varied significantly in the use of
worry to control unwanted thoughts (F(2, 78)¼3.94; P¼0.024),
with non-cases having significantly lower worry scores and stable
cases the highest.
Depression
Occasional cases and stable cases were combined due to a low
number of patients in stable cases. This resulted in two groups of
patients: ‘non-cases’ (n¼47) and ‘cases’ (n¼38). Comparisons of
the two depression profile groups indicated statistically significant
differences between the two groups with respect to subjective
physical health rating scores (U¼666.500, P¼0.038), use of anti-
depressants (w
2 (1)¼8.91, P¼0.003), length of time since cancer
diagnosis (t(83)¼2.87; P¼0.005), stage of disease (U¼669.500,
P¼0.027) and KP (U¼601.500, P¼0.018). Non-cases self-rated
their health status as better compared with cases (medians: non-
cases 5; cases 4). Significantly more patients in the cases group had
taken anti-depressants. There was a longer time since diagnosis in
non-cases (mean¼61 days) than in cases (mean¼45 days).
Patients in the cases group had more advanced FIGO stage (stage
III or IV) and lower KP scores than those in non-cases. Patients in
the cases group reported higher neuroticism (t(80)¼ 4.05,
Po0.001) and used more worry as a coping strategy to control
unwanted thoughts (t(79)¼ 2.33, P¼0.022) than non-cases.
Predictors of persistent psychological disorder
Predictors of anxiety profile group Age, marital status, education,
length of time since cancer diagnosis, neuroticism, worry and
punishment entered the first model of the Multinomial Logistic
Regression to identify significant independent predictors of
anxiety profile groups. The overall statistics for the final equation
were w
2 (4)¼38.53, Po0.001. Marital status (P¼0.041) and
neuroticism (Po0.001) were overall significant and independent
predictors of anxiety profile group. Married women (OR¼9.38;
95% CI (1.2, 73.36) and those with greater neuroticism (OR¼1.59;
95% CI (1.3, 1.95) were at higher risk of being in group 3 (stable
cases) compared with no caseness of anxiety. The risk of being a
stable case increases by 9.38 if the patient was married compared
with not being married and by 1.59 for every unit increase in
neuroticism.
Predictors of depression profile group Length of time since cancer
diagnosis, KP, stage of disease, subjective physical health rating,
current mental health problems, use of anti-depressants, neuroti-
cism, distraction, worry and social control entered the model of the
Table 4 Descriptive statistics for the psychological variables for the total sample, for the anxiety profile groups, and for the depression profile groups
Anxiety profile groups Depression profile groups
Psychological
variables Total sample
Group 1 (stable
non-cases)
Group 2
(occasional cases)
Group 3
(stable cases)
Group 1 (stable
non-cases)
Group 2
(cases)
Neuroticism
a,b
n 114 21 43 18 45 37
Mean (s.d.) 10.21 (5.56) 5.38 (4.82) 10.07 (4.39) 14.5 (4.9) 7.78 (5.14) 12.35 (5.02)
Perceived criticism
c
n 118 21 44 19 46 38
Median (range) 18.8 (0.3–20) 19.5 (9.8–20) 19.3 (0.93–20) 14.1 (0.3–20) 19.26 (0.28–20) 19.21 (6.08–20)
Social support
c
n 119 22 44 19 47 38
Median (range) 0.54 (0–28.9) 0.14 (0–4.5) 0.72 (0.4 -15.6) 0.45 (0–10.6) 0.36 (0–15.63) 0.63 (0–10.8)
Distraction
n 115 21 42 18 45 36
Mean (s.d.) 16.25 (3.82) 16.95 (4.67) 16.21 (3.84) 15.22 (3.69) 16.89 (3.69) 15.31 (4.32)
Punishment
c
n 114 21 42 18 45 36
Median (range) 9 (6–18) 9 (6–16) 9 (6–16) 10 (7–16) 9 (6–16) 9 (6–16)
Re-Appraisal
n 115 22 42 18 45 36
Mean (s.d.) 11.43 (3.30) 11.67 (3.68) 11.55 (3.41) 11.44 (3.29) 11.62 (3.62) 11.47 (3.18)
Worry
a,b,d
n 113 22 42 18 45 36
Mean (s.d.) 10.19 (3.20) 8.71 (2.72) 10.50 (3.05) 11.44 (3.78) 9.51 (2.90) 11.17 (3.49)
Median (range) 10.00 (6–20) 8 (6–17) 10 (6–20) 14 (6–23) 9 (6–17) 10 (6–20)
Social control
e
n 114 22 42 18 45 36
Mean (s.d). 13.35 (3.39) 13.81 (1.66) 13.45 (3.83) 13 (4.39) 13.96 (2.82) 12.81 (4.19)
Median (range) 14.00 (6–23) 14 (9–16) 14 (6–23) 12.5 (6–20) 15 (7–20) 13 (6–23)
n¼number of patients; s.d.¼standard deviation.
aIndicates statistically significant differences in the anxiety profile groups.
bIndicates statistically significant differences in the
depression profile groups.
cThe data were not normally distributed for these variables in the total sample and in the anxiety and depression profile groups; therefore, the median
and range are displayed.
dThe data were not normally distributed for this variable in the total sample; therefore, the median and range are also displayed.
eThe data were not
normally distributed for this variable in the anxiety profile groups; therefore, the median and range are also displayed.
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sBinary Logistic Regression. The overall statistics for the final
equation were w
2 (2)¼17.89, Po0.0001. Neuroticism (P¼0.005)
and use of anti-depressants (P¼0.027) were significant and
independent predictors of depression profile group. Patients who
used anti-depressants (OR¼5.073; 95% CI (1.2, 21.3)) and had
higher neuroticism scores (OR¼1.17; 95% CI (1.05, 1.3)) were
more likely present in the cases group. The likelihood of being a
case increased by 5.073 if the patient used anti-depressants and by
1.17 for every unit increase in neuroticism scores.
DISCUSSION
Our study is the first to assess anxiety and depression in patients
with ovarian cancer prospectively and longitudinally over the
illness course and treatment. We approached consecutive referrals
to a specialist cancer centre of patients who were new cases of
ovarian cancer before the commencement of their treatment
regimen. This allowed us to assess psychological morbidity over a
standard treatment regimen and time period. Thus, avoiding as
much as possible the heterogeneity of patients and timing that
potentially confounds psychological research in cancer patients.
Secondly, we assessed patients over four assessment points so as to
investigate the persistence of psychological disorder, thus avoiding
the difficulties inherent in cross-sectional studies. We have also
assessed ‘cases’ of anxiety and depression rather than symptoms so
as to identify clinically significant levels of psychological morbidity
rather than just distress, which may be understandable, transitory
and less clinically important. Our results support previous findings
that anxiety and depression are present after a recent diagnosis of
ovarian cancer, and during the treatment of the disease and the
follow-up period (Newport and Nemeroff, 1998; Williams and
Dale, 2006). We investigated the persistence of psychological
disorders by studying the individual variability of anxiety and
depression caseness across time. A large number of patients were
cases of anxiety and depression on some occasions, although in
many this was a temporary condition. Transitory psychological
disorders may occur at various stages of the illness and its
treatment, but once the crises fade, the disorders remit (Massie
and Popkin, 1998). In general, it seems that the majority of women
were anxious to a significant degree at some point during their
treatment and follow-up. Anxiety is a response to threat, and the
diagnosis and treatment may constitute a threat for many patients.
The majority of women adjust to their illness (Andersen et al, 1989;
Hamilton, 1999), but a proportion of patients do develop a
persistent psychological disorder, which is more likely to be
anxiety. Persistent clinical depression is relatively uncommon.
Marital status and neuroticism were independent predictors of
anxiety caseness, whereas use of anti-depressants and neuroticism
were the best predictors of depression caseness. Previous studies
have shown equivocal results between marital status and
psychological distress (Harrison and Maguire, 1994; Mundy et al,
2000; Zabora et al, 2001). Some consequences associated with
ovarian cancer may affect married women more directly, such as
having young children and sexual problems (Howell et al, 2003).
Unsurprisingly, and consistent with previous studies (Costanzo
et al, 2007), women who used anti-depressants were more likely to
be depressed. The use of anti-depressants may indicate that
women presented levels of psychological symptoms that led their
physician to prescribe medication. Although our study failed to
find associations between current and past psychiatric history,
earlier studies have found previous psychiatric history to be a
predisposing factor to psychological disorders in cancer patients
(Berard et al, 1998; Costanzo et al, 2007).
In this study, neuroticism was associated with persistent
psychological morbidity. This is a consistent finding in the general
literature (Ormel and Wohlfarth, 1991; Clark et al, 1994; Holeva
and Tarrier, 2001) and in cancer patients, in particular (Ranchor
et al, 2002; Millar et al, 2005). An individual with high neuroticism
experiences more worries, uncertainties, anxiety, depression, and
psychosomatic symptoms and has poor coping under stress
(Eysenck and Eysenck, 1991). Thus, it would not be unexpected
that higher neuroticism would be associated with anxiety and
depression, as all of these elements are characteristics of these
disorders. High scores on neuroticism in the early stages of cancer
could well increase vulnerability to these personality charac-
teristics escalating to full symptoms when exposed to the threat
and uncertainty of cancer treatment.
Contrary to our prediction, perceived social support was not
associated with psychological morbidity. These results were
surprising, as social support has been identified previously as an
important factor associated with psychological distress and
disorders in patients with ovarian cancer (Nordin et al, 2001;
Hipkins et al, 2004; Norton et al, 2005). This finding may reflect
the nature of the sample recruited. Patients in our study seemed to
have very good social support and relationships with significant
others so that there was little variance in the measure, suggesting
that ovarian cancer may have brought the patient closer to their
significant others (Hamilton, 1999) or that these patients already
had supportive significant others before the diagnosis.
The use of worry as a strategy to cope with unwanted thoughts
was significantly associated with anxiety and depression over time.
Worry relates to persistent rumination in an attempt at problem
solving (Matthews and Wells, 1996). Our results confirm that the
worry control strategy seems to be inappropriate for controlling
intrusive thoughts. This is consistent with studies showing that
measures of anxiety and obsessive-compulsive symptoms were
related to worry (Wells and Davies, 1994), and individuals who
recovered from posttraumatic stress disorder and/or depression
were less likely to use worry to control unwanted thoughts than
those who did not (Reynolds and Wells, 1999). Worry as a coping
strategy inhibits emotional processing by draining the attentional
resources. By diverting attention away from the cognitive
operations necessary to support emotional processing, it promotes
the development and maintenance of emotional vulnerability
(Wells and Matthews, 1996).
Our results also showed that women who were persistent cases
of anxiety were younger than women that were not cases, and there
was a trend towards younger women being persistent cases of
depression. This is consistent with previous findings in ovarian
cancer patients (Borduka-Bevers et al, 2000; Hipkins et al, 2004;
Norton et al, 2004). For these women, the consequences of, and
difficulty in adjusting to, ovarian cancer may be greater because of
disruption to family or career plans and impairment of sexual
functioning. The management of ovarian cancer may induce
premature menopause and the loss of childbearing capacity.
Furthermore, some women have young children whom they fear
they may not see them grow up, which constitutes an additional
source of distress.
Lower subjective physical health ratings were significantly
associated with caseness of depression. This result agrees with
that of our earlier study (Hipkins et al, 2004). It is possible that
patients with higher psychological morbidity report more physical
symptoms. Psychological disorders may increase sensitivity to
physical health and focus attention on physical sensations, which
as a result become amplified. Our findings also indicate that
women who had more recently been diagnosed with ovarian
cancer present higher psychological morbidity (Norton et al,
2004). It may be that these women remain acutely distressed and
have not had enough time to adjust to their diagnosis. Although
the association between medical factors and psychological
morbidity in ovarian cancer patients is controversial, our results
support the view that women with poor performance status and
advanced stage of disease presented higher levels of depression
(Kornblith et al, 1995; Borduka-Bevers et al, 2000; Norton et al,
2004). In agreement with Hipkins et al (2004), response to
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with psychological morbidity.
There are limitations to this study. First, we analysed a sample
that was representative of ovarian cancer patients in the UK
regarding disease stage and age of diagnosis (Incidence of Cancer
in UK, 2004). Nevertheless, the results may not generalise to
women of different ethnic background or socioeconomic status
and for those with other types of cancer. Second, we followed
patients for only 3 months after the end of chemotherapy, and
levels of psychological morbidity after this time remain unknown.
Third, results showed that women scoring high in neuroticism and
worry were more likely to be persistent cases of psychological
disorders. This may suggest that these measures obtained at time 1
predicted subsequent anxiety and depression. However, it can be
argued that these women were more severely anxious and
depressed at time 1 because exposure to such stressful situations
caused changes in personality and coping skills. Last, we aimed to
assess a cohort of patients at four different time points over the 6-
month period of their treatment and follow-up. We were successful
in collecting complete data from over 70% of the cohort. But there
were missing data and these were unlikely to have been missing at
random and may have introduced some bias. There may have been
pragmatic reasons why some assessments were not complete or the
patient’s illness could have been influential. Eleven patients died
while in the study.
In practical terms, our results support the need of routine and
repetitive screening for identification of persistent psychological
morbidity and the provision of adequate and appropriate
psychological management. There is a question as to whether
scarce resources for psychological treatment should be used to
target only those whose psychological disorders persist, or should
be used more generally to target early in treatment to prevent
persistent morbidity or whether all, even transitory, morbidity is a
legitimate treatment target. Furthermore, whether screening for
risk factors based on predictive associations, such as high levels of
neuroticism or ineffective coping strategies, would identify those at
high risk of persistent morbidity and serve as treatment
candidates. At least in depression, there appears to be an argument
for the use of efficacious psychological treatments, such as
cognitive behaviour therapy, as the use of anti-depressants is
associated with more severe psychological morbidity so that
treatment response can be assumed to be incomplete.
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